(Q36787311)

16 August 2017

1 reference

title

Efavirenz: a review (English)

1 reference

16 August 2017

1 reference

Saskia M E Vrouenraets

1

1 reference

16 August 2017

Ferdinand W N M Wit

2

1 reference

16 August 2017

Jacqueline van Tongeren

3

1 reference

16 August 2017

Joep M A Lange

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

851-871

1 reference

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Genetic correlates of efavirenz hypersusceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.851

21 January 2018

Identifiers

DOI

10.1517/14656566.8.6.851

1 reference

16 August 2017

1 reference